Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study

Martin J. van den Bent*, Brigitta Baumert, Sara C. Erridge, Michael A. Vogelbaum, Anna K. Nowak, Marc Sanson, Alba Ariela Brandes, Paul M. Clement, Jean Francais Baurain, Warren P. Mason, Helen Wheeler, Olivier L. Chinot, Sanjeev Gill, Matthew Griffin, David G. Brachman, Walter Taal, Roberta Ruda, Michael Weller, Catherine McBain, Jaap ReijneveldRoelien H. Enting, Damien C. Weber, Thierry Lesimple, Susan Clenton, Anja Gijtenbeek, Sarah Pascoe, Ulrich Herrlinger, Peter Hau, Frederic Dhermain, Irene van Heuvel, Roger Stupp, Ken Aldape, Robert B. Jenkins, Hendrikus Jan Dubbink, Winand N. M. Dinjens, Pieter Wesseling, Sarah Nuyens, Vassilis Golfinopoulos, Thierry Gorlia, Wolfgang Wick, Johan M. Kros

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)1645-1653
Number of pages9
JournalLancet
Volume390
Issue number10103
DOIs
Publication statusPublished - 7 Oct 2017

Keywords

  • BRAIN-TUMOR GROUP
  • LOW-GRADE GLIOMA
  • EUROPEAN ORGANIZATION
  • OLIGODENDROGLIAL TUMORS
  • IDH2 MUTATIONS
  • III TRIAL
  • PROCARBAZINE
  • VINCRISTINE
  • GLIOBLASTOMA
  • CHEMOTHERAPY

Cite this